Court Revived Antitrust Claims Against Align Technology
The ruling forces the company to defend its business practices regarding product interoperability.
Updated on Oct. 5, 2026 in Healthcare
Live Poll
Should companies be allowed to limit third-party interoperability to protect their own market share?
The Court of Appeals for the Ninth Circuit has revived an antitrust lawsuit against Align Technology, reversing a previous summary judgment. The case alleges that the company engaged in anticompetitive behavior concerning its clear aligners and digital scanners.
Why it matters
The ruling centers on whether a dominant firm can leverage patent litigation to block interoperability with competitor systems. Businesses must now watch how these claims evolve, as they could impact how firms maintain closed digital ecosystems in the medical technology market.
The Ninth Circuit Court of Appeals reversed a summary judgment in favor of Align Technology, effectively reviving monopolization claims that were previously dismissed. The full extent of potential damages or injunctive relief remains unresolved as the case returns to lower court proceedings.
The players
Align Technology
A global medical device company that designs and manufactures the Invisalign clear aligner system and iTero digital intraoral scanners.
3Shape
A developer of 3D scanning and software solutions for dental and orthodontic professionals that maintains an open system for intraoral data.
Ninth Circuit Court of Appeals
A federal appellate court with jurisdiction over antitrust disputes and the authority to set legal precedents for lower district courts.
The details
The court found that a reasonable factfinder could conclude that Align Technology utilized patent litigation as a pretext to terminate interoperability with 3Shape’s open systems. By preventing competitors from integrating with 3Shape technology, the firm allegedly aimed to insulate its Invisalign product from direct market competition. This decision marks a significant hurdle for the company as it must now defend its past litigation and product-integration strategies in court.
Timeline
October 5, 2026: The Ninth Circuit Court of Appeals issued the opinion reviving the antitrust case.
Market Landscape
This ruling clarifies the application of the Sherman Antitrust Act in cases where dominant firms use intellectual property claims to block technical integration. The decision aligns with broader judicial scrutiny regarding how companies use patent litigation as a mechanism for market dominance.
Business owners relying on proprietary or open-system medical software should monitor this case for guidance on interoperability requirements. Consult with legal counsel to evaluate how internal patent-enforcement strategies align with evolving interpretations of antitrust law.
The takeaway
The court's decision underscores the legal risks of using patent litigation to intentionally degrade competitive interoperability. Operators should audit their own competitive strategies to ensure that intellectual property enforcement does not cross the line into anticompetitive conduct.
Further reading
For more on industry-wide trends, visit the Healthcare section.
Live Poll
Should companies be allowed to limit third-party interoperability to protect their own market share?
